tradingkey.logo
搜尋

AGMB.NB

AGMB
添加自選
10.550USD
-0.490-4.44%
收盤 05/15, 16:00美東報價延遲15分鐘
514.17M總市值
虧損本益比TTM

AGMB.NB

10.550
-0.490-4.44%

關於 AGMB.NB 公司

Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

AGMB.NB簡介

公司代碼AGMB
公司名稱Agomab Therapeutics NV
上市日期Feb 06, 2026
CEOKnotnerus (Tim)
員工數量- -
證券類型Depository Receipt
年結日Feb 06
公司地址Posthoflei 1/6
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Belgium
郵編2600
電話
網址https://agomab.com/
公司代碼AGMB
上市日期Feb 06, 2026
CEOKnotnerus (Tim)

AGMB.NB公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--
Mr. Pierre Kemula
Mr. Pierre Kemula
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David R. Epstein
Mr. David R. Epstein
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Angelika Jahreis
Ms. Angelika Jahreis
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Colin Bond
Mr. Colin Bond
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 5月9日 週六
更新時間: 5月9日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.90%
Pontifax Venture Capital
6.71%
Sanofi SA
5.65%
EQT Life Sciences
2.28%
abrdn Inc.
1.44%
其他
74.02%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.90%
Pontifax Venture Capital
6.71%
Sanofi SA
5.65%
EQT Life Sciences
2.28%
abrdn Inc.
1.44%
其他
74.02%
股東類型
持股股東
佔比
Investment Advisor
9.91%
Venture Capital
9.00%
Corporation
5.65%
Investment Advisor/Hedge Fund
1.54%
Hedge Fund
0.41%
Individual Investor
0.02%
其他
73.47%

機構持股

更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
10
10.27M
20.86%
+10.21M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
4.87M
9.9%
+4.87M
--
Feb 27, 2026
EQT Life Sciences
1.13M
2.29%
+1.13M
--
Feb 09, 2026
Knotnerus (Tim)
10.82K
0.02%
+10.82K
--
Feb 06, 2026
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI